Skip to main content

Table 2 Treatment modifications

From: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

  FAS population
Dose interruptionsa: n (%) 204 (31.2)
 Reasons: n (%)
  Patient willingness 8 (3.9)
  General health deterioration 29 (14.2)
  Adverse event (treatment-related or not) 173 (84.8)
  Other 9 (4.4)
Dose reduction: n (%) 278 (42.5)
 Reasons: n (%)
  Patient willingness 6 (2.2)
  General health deterioration 66 (23.7)
  Disease progression 2 (0.7)
  Adverse event (treatment-related or not) 226 (81.3)
  Other 20 (7.2)
Any kind of dose modification: n (%) 329 (50.3)
  1. aPermanent or temporary interruption